MA26845A1 - CRYSTALLINE FORM OF 4-CARBOXYAMINO-2-ETHYL-1,2,3,4- - Google Patents

CRYSTALLINE FORM OF 4-CARBOXYAMINO-2-ETHYL-1,2,3,4-

Info

Publication number
MA26845A1
MA26845A1 MA26653A MA26653A MA26845A1 MA 26845 A1 MA26845 A1 MA 26845A1 MA 26653 A MA26653 A MA 26653A MA 26653 A MA26653 A MA 26653A MA 26845 A1 MA26845 A1 MA 26845A1
Authority
MA
Morocco
Prior art keywords
carboxyamino
ethyl
crystalline form
crystalline
Prior art date
Application number
MA26653A
Other languages
French (fr)
Inventor
John Meldrum Allen Douglas
Anthony Appleton Troy
Lawrence Tickner Derek
Robinson Brostrom Lyle
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26845A1 publication Critical patent/MA26845A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA26653A 1999-11-30 2002-05-27 CRYSTALLINE FORM OF 4-CARBOXYAMINO-2-ETHYL-1,2,3,4- MA26845A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16805199P 1999-11-30 1999-11-30

Publications (1)

Publication Number Publication Date
MA26845A1 true MA26845A1 (en) 2004-12-20

Family

ID=22609901

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26653A MA26845A1 (en) 1999-11-30 2002-05-27 CRYSTALLINE FORM OF 4-CARBOXYAMINO-2-ETHYL-1,2,3,4-

Country Status (28)

Country Link
EP (1) EP1246804A1 (en)
JP (1) JP2003515592A (en)
KR (1) KR20020058057A (en)
CN (1) CN1402711A (en)
AP (1) AP2002002531A0 (en)
AU (1) AU1048801A (en)
BG (1) BG106854A (en)
BR (1) BR0015836A (en)
CA (1) CA2392979A1 (en)
CO (1) CO5271716A1 (en)
EA (1) EA200200510A1 (en)
EC (1) ECSP003792A (en)
EE (1) EE200200277A (en)
GT (1) GT200000199A (en)
HU (1) HUP0203521A2 (en)
IL (1) IL149097A0 (en)
IS (1) IS6338A (en)
MA (1) MA26845A1 (en)
MX (1) MXPA02005354A (en)
NO (1) NO20022558L (en)
OA (1) OA12099A (en)
PA (1) PA8506301A1 (en)
PE (1) PE20010904A1 (en)
PL (1) PL355892A1 (en)
TN (1) TNSN00231A1 (en)
TR (1) TR200201446T2 (en)
UY (1) UY26454A1 (en)
WO (1) WO2001040190A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
TNSN03139A1 (en) 2001-06-21 2005-12-23 Pfizer Prod Inc SELF-EMULSIBLE FORMULATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS
GT200200170A (en) 2001-09-28 2003-05-23 PREPARATION OF INHIBITOR OF CETP ANHIDRO
PT1469833T (en) * 2002-02-01 2021-07-13 Bend Res Inc Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
EP1920766B1 (en) * 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
ATE395044T1 (en) 2002-02-01 2008-05-15 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS OF AMORPHIC DISPERSIONS OF ACTIVE INGREDIENTS AND LIPOPHILIC MICROPHASE-FORMING MATERIALS
ES2277142T3 (en) 2002-08-30 2007-07-01 Japan Tobacco Inc. DIBENCILAMINE COMPOSITE AND ITS MEDICINAL USE.
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7211672B2 (en) 2002-10-04 2007-05-01 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
BR0317521A (en) 2002-12-20 2005-11-16 Pfizer Prod Inc Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
JP2006521344A (en) * 2003-03-28 2006-09-21 ファイザー・プロダクツ・インク 1,2,4-substituted 1,2,3,4-tetrahydro- and 1,2-dihydro-quinoline and 1,2,3,4 as CETP inhibitors for the treatment of atherosclerosis and obesity -Tetrahydro-quinoxaline derivatives
JP2007501218A (en) 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク Pharmaceutical composition of adsorbate of amorphous drug and lipophilic microphase-forming substance
DK1670768T3 (en) 2003-10-08 2009-11-09 Lilly Co Eli Compounds and Methods to Treat Dyslipidemia
JP4922924B2 (en) * 2004-04-13 2012-04-25 メルク・シャープ・エンド・ドーム・コーポレイション CETP inhibitor
EP1761521A1 (en) * 2004-06-24 2007-03-14 Eli Lilly And Company Compounds and methods for treating dyslipidemia
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
WO2006033004A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds as cetp inhibitors
WO2006091674A1 (en) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
WO2006098394A1 (en) * 2005-03-14 2006-09-21 Japan Tobacco Inc. Method for inhibiting lipid absorption and lipid absorption inhibitor
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
AR065670A1 (en) 2007-03-09 2009-06-24 Indigene Pharmaceuticals Inc COMBINATION OF METFORMIN R - (+) LIPOATE AND ANTIHIPERLIPIDEMIC AGENTS FOR THE TREATMENT OF DIABETIC HYPERGLUCEMIA AND DIABETIC COMPLICATIONS
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
TWI450896B (en) 2009-06-30 2014-09-01 Lilly Co Eli Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
MX2017000582A (en) 2014-07-30 2017-04-27 Hoffmann La Roche Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
WO1998033775A1 (en) * 1997-02-03 1998-08-06 American Home Products Corporation 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
EP1246804A1 (en) 2002-10-09
EA200200510A1 (en) 2002-10-31
AP2002002531A0 (en) 2002-06-30
JP2003515592A (en) 2003-05-07
CO5271716A1 (en) 2003-04-30
IL149097A0 (en) 2002-11-10
CN1402711A (en) 2003-03-12
AU1048801A (en) 2001-06-12
KR20020058057A (en) 2002-07-12
CA2392979A1 (en) 2001-06-07
WO2001040190A1 (en) 2001-06-07
PL355892A1 (en) 2004-05-31
TR200201446T2 (en) 2002-11-21
MXPA02005354A (en) 2002-12-11
UY26454A1 (en) 2001-07-31
PA8506301A1 (en) 2002-08-26
GT200000199A (en) 2002-05-23
EE200200277A (en) 2003-10-15
TNSN00231A1 (en) 2002-05-30
HUP0203521A2 (en) 2003-02-28
OA12099A (en) 2006-05-04
BG106854A (en) 2002-12-29
ECSP003792A (en) 2002-04-23
NO20022558D0 (en) 2002-05-29
IS6338A (en) 2002-04-12
NO20022558L (en) 2002-05-29
BR0015836A (en) 2002-08-06
PE20010904A1 (en) 2001-09-10

Similar Documents

Publication Publication Date Title
MA26845A1 (en) CRYSTALLINE FORM OF 4-CARBOXYAMINO-2-ETHYL-1,2,3,4-
MA27349A1 (en) CRYSTALLINE COMPOSITION CONTAINING ESCITALOPRAM.
DZ2817A1 (en) Polymorphic form of clopidogrel hydrogen sulfate.
ID26743A (en) DURING 1,2,4,5-TETRAHIDRO-BENZO [D] AZEPIN
NO20012857D0 (en) Controlled release galantamine composition
PL380733A1 (en) New derivatives of 3,3-diphenylpropylamines
DE69933287D1 (en) 12,13-MODIFIED EPOTHILON DERIVATIVES
DE69907162D1 (en) ORGANOPHILE PHYLLOSILICATES
HUP0204034A3 (en) Stable salts of novel derivatives of 3,3-diphenylpropylamines
MA26500A1 (en) NEW FORM OF S-OMERPRAZOLE
ID26310A (en) PRODUCTION OF CONTINUED-1,3-DIOXOL-2-ONA
DE69920730D1 (en) AQUEOUS COMPOSITION
ID29149A (en) ADJUVAN COMPOSITION
AR027907A1 (en) COMPOSITION OF CONTROLLED RELEASE
DE69919255D1 (en) The engraver
IL137518A0 (en) Derivatives of 1,2,4-oxadiazolone
DE60025958D1 (en) 14,15-BETA-METHYLENE SUBSTITUTED ANDROGENE
AR028607A1 (en) DERIVATIVES OF 1,4-DIAZEPAN-2,5-DIONA
ID22456A (en) PROCESS OF MAKING DIESTER-DIESTER 2,3,5-TRIMETHYL HYDROXININON
ID27686A (en) TURUNAN 3- (2-OKSO- [1,3] BIPIROLIDINIL-3-ILDENAMETIL) -SEFEM
DE69907161D1 (en) 5 'DEOXYCYTIDINE DERIVATIVES
DE69917392D1 (en) Crystalline polymer composition
NO20015397L (en) 1,5-Benzodiazepine derivatives
DE59907066D1 (en) blanket
ITMI992457A0 (en) PROCEDURE FOR THE PREPARATION OF (S)-N-TERBUTYL-1,2,3,4-TETRAHYDROIS OCHINOLIN-3-CARBOXYAMIDE